Table 1A Patient demographics
All patients (n=37) | Patients without significant cancer (n=5) | Patients with significant cancer (n=32) | |
|---|---|---|---|
Age | 68 (57–80) | 69 (62–79) | 68 (57–80) |
PSA at time of MRI | 4.5 (0.5–60) | 2.4 (0.5–5.8) | 4.75 (0.6–60) |
Time between end of DXT and MRI (months) | 66 (24–166) | 57 (54–72) | 66.5 (24–166) |
Time between MRI and biopsy (months) | 2 (1–10) | 2 (1–10) | 1.5 (1–6) |
Total biopsy cores/patient | 41 (20–85) | 33 (22–41) | 45 (20–85) |
Positive cores/patient (%) | 17 (0–96) | 0 (0–3) | 20.5 (6–96) |
Clinical stage at diagnosis | |||
1b | 1 | 0 | 1 |
1c | 8 | 1 | 7 |
2a | 7 | 3 | 4 |
2b | 1 | 1 | 0 |
2c | 4 | 0 | 4 |
3a | 10 | 0 | 10 |
3b | 6 | 0 | 6 |
Gleason score at diagnosis | |||
3+3 | 15 | 2 | 13 |
3+4 | 9 | 1 | 8 |
4+3 | 2 | 0 | 2 |
4+4 | 4 | 1 | 3 |
4+5 | 6 | 1 | 5 |
5+4 | 1 | 0 | 1 |
Hormones before MRI | |||
Yes | 27 | 4 | 23 |
No | 10 | 1 | 9 |
